Oncotarget

Research Papers:

Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma

Marc A. Schneider _, Thomas Muley, Nicolas C. Kahn, Arne Warth, Michael Thomas, Felix J.F. Herth, Hendrik Dienemann and Michael Meister

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:71285-71297. https://doi.org/10.18632/oncotarget.12474

Metrics: PDF 720 views  |   HTML 1753 views  |   ?  


Abstract

Marc A. Schneider1,6, Thomas Muley1,6, Nicolas C. Kahn1,4,6, Arne Warth2,6, Michael Thomas3,6, Felix J.F. Herth4,6, Hendrik Dienemann5,6 and Michael Meister1,6

1 Translational Research Unit, Thoraxklinik at University Hospital Heidelberg, Roentgenstraße, Heidelberg, Germany

2 Institute of Pathology, University of Heidelberg, Heidelberg, Germany

3 Department of Thoracic Oncology, Thoraxklinik at University Hospital Heidelberg, Roentgenstraße, Heidelberg, Germany

4 Department of Pneumology and Critical Care Medicine, Thoraxklinik at University Hospital Heidelberg, Roentgenstraße, Heidelberg, Germany

5 Department of Surgery, Thoraxklinik at University Hospital Heidelberg, Roentgenstraße, Heidelberg, Germany

6 Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany

Correspondence to:

Marc A. Schneider, email:

Keywords: MPM, glycodelin, SMRP, biomarker, follow-up

Received: September 18, 2016 Accepted: September 25, 2016 Published: October 04, 2016

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a short survival time arising from the mesothelial cells of the pleura. Soluble mesothelin-related peptide (SMRP), osteopontin or EFEMP1 (Fibulin-3) are well described biomarkers for malignant mesothelioma with moderate sensitivity and specificity. In this study, we characterized the expression of glycodelin, a marker for risk pregnancy, in MPM by RNA and protein analyses and investigated its potential as a MPM biomarker. We were able to detect glycodelin in the serum of MPM patients. Compared to benign lung diseases, the serum levels were significant increased. Patients with high glycodelin serum levels revealed a worse overall survival. The glycodelin serum levels correlated with the tumor response to treatment. A comparison of SMRP and glycodelin serum measurement in a large patient cohort demonstrated that the detection of both soluble factors can increase the reliable diagnostic of MPM. Glycodelin was highly expressed in MPM tumors. Analyses of a tissue micro array indicated that the immunomodulatory form glycodelin A was expressed in MPM and correlated with the survival of the patients. Altogether, glycodelin seems to be a new potential biomarker for the aggressive malignant pleural mesothelioma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12474